Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Menü

Klinische Studien von BMS suchen
BMS-Symbol für "Studie, für die rekrutiert wird"

Recruiting

Studien-Nr. CA240-0029  |   NCT07063745

A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

Zusammenfassung

  • Phase 2/Phase 3
  • Symbol für männliches und weibliches Geschlecht
  • 18+
    Altersgruppe
  • 100
    Standorte
  • BMS-Symbol für "Studie, für die rekrutiert wird"
    Recruiting

Überblick

The purpose of this study is to compare the clinical benefit of the combination of BMS-986504 (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemotherapy in first-line metastatic non-small cell lung cancer participants with homozygous MTAP deletion

Druckmedium-alt Druckmedium
email E-Mail

Nächstgelegenes Prüfzentrum

Wichtigste Einschlusskriterien

Einschlusskriterien

Symbol für Einschlusskriterien img
  • Participants must have Metastatic (Stage IV or recurrent) non-small cell lung cancer (NSCLC) (as defined by the American Joint Committee on Cancer, Ninth Edition) with no prior systemic anti-cancer therapy for metastatic disease.
    1. Participants must have histologically confirmed diagnosis of NSCLC and homozygous methylthioadenosine phosphorylase (MTAP) deletion or MTAP loss.
      1. Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
        1. Participants must have at least 1 measurable lesion as per RECIST v1.1.

          Ausschlusskriterien

          Symbol für Ausschlusskriterien
          • Nonsquamous participants must not have documented targetable oncogenic mutation or actionable genetic alterations (AGAs) for which there is a standard of care (SoC) available as first-line (1L) therapy.
            1. Participants must not have symptomatic brain metastases or spinal cord compression.
              1. Participants must not have any prior systemic therapy (chemotherapy, immunotherapy, targeted therapy, or biological therapy) for metastatic non-small cell lung cancer (mNSCLC). Note: One cycle of SoC treatment prior to randomization will be allowed for participants who require immediate treatment if clinically indicated.
                1. Participants must not have any known or suspected impairment of gastrointestinal function that may prohibit the ability to absorb or swallow an oral medication without chewing or crushing.
                  Zusätzliche Informationen*
                  • Other protocol-defined Inclusion/Exclusion criteria apply.

                    Behandlungsmöglichkeiten

                    Studienarme

                    ZUGEWIESENE BEHANDLUNG

                    Studienarme

                    Active Comparator: Arm A: BMS-986504 + Pembrolizumab + Chemotherapy

                    ZUGEWIESENE BEHANDLUNG
                    • Drug: BMS-986504, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel

                    Studienarme

                    Active Comparator: Arm B: BMS-986504 + Pembrolizumab + Chemotherapy

                    ZUGEWIESENE BEHANDLUNG
                    • Drug: BMS-986504, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel

                    Studienarme

                    Placebo Comparator: Arm C: Placebo + Pembrolizumab + Chemotherapy

                    ZUGEWIESENE BEHANDLUNG
                    • Drug: Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel
                    • Other: Placebo

                    Studienarme

                    Placebo Comparator: Arm D: Placebo + Pembrolizumab + Chemotherapy

                    ZUGEWIESENE BEHANDLUNG
                    • Drug: Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel
                    • Other: Placebo

                    Studienarme

                    Active Comparator: Arm E: BMS-986504 + Pembrolizumab + Chemotherapy

                    ZUGEWIESENE BEHANDLUNG
                    • Drug: BMS-986504, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel

                    Studienarme

                    Placebo Comparator: Arm F: Placebo + Pembrolizumab + Chemotherapy

                    ZUGEWIESENE BEHANDLUNG
                    • Drug: Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel
                    • Other: Placebo
                    Prüfen Sie, ob eine der klinischen Studien für Sie infrage kommt
                    Kommt die Studie für Sie infrage
                    Beantworten Sie einige Fragen zu Ihrer Gesundheit, um festzustellen, ob diese Studie für Sie infrage kommt
                    Geeignete Studie
                    Wenn ihnen eine passende Studie angezeigt wird, klicken Sie auf die Studie, damit Sie die Liste der Prüfzentren angezeigt bekommen.
                    Wählen Sie einen Prüfzentrumsstandort aus
                    Wählen Sie einen Prüfzentrumsstandort aus, der für Sie günstig ist
                    Registrieren
                    Geben Sie Ihre Kontaktdaten ein, damit das Prüfzentrum mit Ihnen Kontakt aufnehmen kann.

                    Unterstützen Sie uns dabei, Ihre Nutzung der Website zu optimieren! Teilen Sie Ihr Feedback mit unserem Team bei BMS Clinical Trials, um die Nutzung der Webseite, Ihre Erfahrungen und die anderer zu verbessern. Vielen Dank!